Third Generation EGFR TKIs for Acquired Resistance

Third Generation EGFR TKIs for Acquired Resistance

Da: GRACEcast
0 0 4 anni fa
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Seguici su Facebook